Epicareer Might not Working Properly
Learn More

Clinical Pharmacy Specialist (Hematology/Oncology)

  • Full Time, onsite
  • Veterans Health Administration
  • Orlando, United States of America
Salary undisclosed

Apply on


Original
Simplified

The primary responsibility of the Clinical Pharmacy Specialist (CPS)/Clinical Pharmacist Practitioner (CPP) in hematology/oncology is the provision of evidence-based pharmaceutical care services through both direct and indirect interactions with patients and providers.

The CPS/CPP serves as a provider with prescriptive authority as outlines in the individual's Scope of Practice.

The CPS/CPP functions as part of the hematology/oncology outpatient clinic, and is most effective when embedded within a team assigned to patients to support continuity of care. The CPS in hematology/oncology may also consult with patients with hematology/oncology pharmacotherapy issues in the acute or primary care settings, if needed.

The CPS/CPP has full responsibility to develop necessary services such as a physician consultation, patient monitoring, patient counseling and medication management clinics within the hematology/oncology setting.

The CPS/CPP promotes and manages drug therapy based on current clinical knowledge that is consistent with policies established at the national, VISN, and local levels.

Work Schedule: Employees may be required to work days, evening, nights, weekends, holidays and/or compressed, tours on a rotating schedule. The hours may vary per the needs of the service and will rotate, on a fair and equitable basis, to include weekends and holidays.
Telework: May be available, pending service approval
Virtual: This is not a virtual position.
Functional Statement #: 80372F
Relocation/Recruitment Incentives: Not Authorized
EDRP Authorized: Former EDRP participants ineligible to apply for incentive.Contact Jamie Wunsch at [email protected], the EDRP Coordinator for questions/assistance.
Permanent Change of Station (PCS): Not Authorized

Starting at $138,578 Per Year (GS 13)